Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type

Clinical Cancer Research

Volumn 18, Issue 15, 2012, Pages 4183-4190

  Ito, Yoshinori ^a   Kimura, Hiroshi ^a   Maeda, Yoshinobu ^b   Hashimoto, Chizuko ^c   Ishida, Fumihiro ^d   Izutsu, Koji ^e   Fukushima, Noriyasu ^f   Isobe, Yasushi ^e   Takizawa, Jun ^g   Hasegawa, Yuichi ^h   Kobayashi, Hajime ⁱ   Okamura, Seiichi ^j   Kobayashi, Hikaru ^l   Yamaguchi, Motoko ^m   Suzumiya, Junji ^k   Hyo, Rie ^a   Nakamura, Shigeo ^a   Kawa, Keisei ⁿ   Oshimi, Kazuo ^e   Suzuki, Ritsuro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

^d SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f SAGA UNIVERSITY   (Japan)

^g NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^h University of Tsukuba School of Medicine   (Japan)

ⁱ Obihiro Kosei Hospital   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^k Fukuoka University Chikushi Hospital   (Japan)

^l Japanese Red Cross Nagano Hospital   (Japan)

^m MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁿ RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; STEROID; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BLOOD ANALYSIS; BRAIN DISEASE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATIONAL STUDY; DNA DETERMINATION; DRUG EFFICACY; DRUG RESPONSE; EPSTEIN BARR VIRUS; FEMALE; GENE DOSAGE; HUMAN; HYPERAMYLASEMIA; HYPONATREMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MALE; NEUTROPENIA; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; ETOPOSIDE; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; METHOTREXATE; MIDDLE AGED; NASAL MUCOSA; NEUTROPENIA; PROGNOSIS; PROSPECTIVE STUDIES; STEROIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864451828     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1064     Document Type: Article

References (32)

1. Rickinson AB, Kieff E. Epstein-Barr Virus. In:Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2007:2655-700.
2. Cohen JI. Epstein-Barr virus infection. New Engl J Med 2000;343:481-92. (Pubitemid 30646489)
3. Williams H, Crawford DH. Epstein-Barr virus: the impact of scientific advances on clinical practice. Blood 2006;107:862-9. (Pubitemid 43156280)
4. Chan JKC, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/Tcell lymphoma, nasal type. In:Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2008:285-8.
5. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009;113:3931-7.
6. Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010;21:1032-40.
7. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 2007;139:532-44. (Pubitemid 350043813)
8. Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009;27:5594-600.
9. Kim SJ, Kim K, Kim BS, Kim CY, Suh C, Huh J, et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009;27:6027-32.
10. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, Lasparaginase, and etoposide (SMILE) chemotherapy for advancedstage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008;99:1016-20. (Pubitemid 351997606)
11. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-cell tumor study group study. J Clin Oncol 2011;29:4410-6.
12. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV)DNAlevels in patientswith EBV-associated lymphoid malignancies. Br J Haematol 2000;111:239-46.
13. Chan KCA, Zhang J, Chan ATC, Lei KIK, Leung S-F, Chan LYS, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003;63:2028-32. (Pubitemid 36538602)
14. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol 2008;18:305-19.
15. Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-70. (Pubitemid 38736543)
16. Chan KC, Leung SF, Yeung SW, Chan AT, Lo YM. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. Clin Cancer Res 2008;14:4809-13.
17. Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104:243-9. (Pubitemid 38879864)
18. Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood 2011;118:6018-22.
19. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999;37:132-6. (Pubitemid 29004193)
20. Wada K, Kubota N, Ito Y, Yagasaki H, Kato K, Yoshikawa T, et al. Simultaneous quantification of Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6DNAin samples from transplant recipients by multiplex real-time PCR assay. J Clin Microbiol 2007;45:1426-32. (Pubitemid 46762394)
21. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res 2002;8:29-34. (Pubitemid 34101456)
22. Gandhi MK, Lambley E, Burrows J, Dua U, Elliott S, Shaw PJ, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006;12:460-4. (Pubitemid 43166136)
23. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61. (Pubitemid 46348180)
24. Drouet E, Brousset P, Fares F, Icart J, Verniol C, Meggetto F, et al. High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. J Med Virol 1999;57:383-9. (Pubitemid 29124258)
25. Gallagher A, Armstrong AA, MacKenzie J, Shield L, Khan G, Lake A, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer 1999;84:442-8. (Pubitemid 29337135)
26. Savoie A, Perpete C, Carpentier L, Joncas J, AlfieriC.Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994;83:2715-22. (Pubitemid 24135866)
27. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994;84:972-84.
28. Wadowsky RM, Laus S, Green M, Webber SA, Rowe D. Measurement of Epstein-Barr virus DNAloads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 2003;41:5245-9. (Pubitemid 37429951)
29. Hakim H, Gibson C, Pan J, Srivastava K, Gu Z, Bankowski MJ, et al. Comparison of various blood compartments and reporting units for the detection and quantification of Epstein-Barr virus in peripheral blood. J Clin Microbiol 2007;45:2151-5. (Pubitemid 47203785)
30. Stevens SJ, Pronk I, Middeldorp JM. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. J Clin Microbiol 2001;39:1211-6. (Pubitemid 32275408)
31. Aalto SM, Juvonen E, Tarkkanen J, Volin L, Haario H, Ruutu T, et al. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007;45:1305-9. (Pubitemid 351411905)
32. Spacek M, Hubacek P, Markova J, Zajac M, Vernerova Z, Kamaradova K, et al. Plasma EBV-DNA monitoring in Epstein-Barr virus-positive Hodgkin lymphoma patients. APMIS 2010;119:10-6.